2F-QMPSBAlso known as SGT-13
A synthetic cannabinoid with a sulfamoyl benzoate core, designed outside the families covered by generic clauses.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₂H₂₀F₂N₂O₄S
CAS 2707165-48-6
- Family
- Synthetic CB receptor agonistNew psychoactive substance
- Molar mass
- 446.50 g/mol
Updated on
In plain terms
2F-QMPSB is a synthetic cannabinoid made in a laboratory, spotted in 2018 in herbal products seized in Europe. Its structure is very different from that of the best-known synthetic cannabinoids. No measurement of its action on the receptors was found, and it is not cited in the French list of narcotics.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to 2F-QMPSB: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 2F-QMPSB.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Agonistno measured value cited
Classified as a cannabinoid receptor agonist (SCRA); no published affinity or efficacy value found
- CB2Agonistno measured value cited
Classified as a cannabinoid receptor agonist (SCRA); no published value found
Pharmacology
2F-QMPSB (SGT-13) belongs to a little-studied group of synthetic cannabinoids with a sulfamoyl benzoate, sulfamoyl benzamide or N-benzoylpiperidine core (Brandt et al. 2021). Brandt et al. recall that the company Stargate International investigated and developed six of these compounds between 2011 and early 2014 with a view to marketing, and that the quinolin-8-yl head group of the series paved the way for PB-22 (SGT-21) and BB-22 (SGT-32). A parcel seized in February 2018 at Malpensa airport supplied the three plant samples in which Tsochatzis et al. (2021) identified 2F-QMPSB, with its acid precursor 2F-MPSBA, by gas chromatography-mass spectrometry, nuclear magnetic resonance (1H, 13C, 19F, 15N) and high-resolution tandem mass spectrometry; it was notified to the EMCDDA on 9 January 2019. Richter et al. (2023) described its in vitro metabolism: ester hydrolysis, catalysed mainly by the human carboxylesterases hCES1 and also non-enzymatic, gives a carboxylic acid detectable only in negative ionisation mode. No measurement of affinity or efficacy at the cannabinoid receptors was found, and no human data.
Key sources.
- Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C. Identification and Analytical Characterization of a Novel Synthetic Cannabinoid-Type Substance in Herbal Material in Europe. Molecules. 2021;26(3) (new tab)PMID 33546439
- Brandt SD, Kavanagh PV, Westphal F, Dreiseitel W, Dowling G, Bowden MJ, Williamson JPB. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233. Drug Test Anal. 2021;13(1):175-196 (new tab)PMID 32880103
- Richter MJ, Wagmann L, Brandt SD, Meyer MR. In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists 2F-QMPSB and SGT-233 Including Isozyme Mapping and Carboxylesterases Activity Testing. J Anal Toxicol. 2023;46(7):e198-e206 (new tab)PMID 36083120
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
History
- Source
- A wholly synthetic compound, with no natural occurrence. It was identified in three samples of herbal material from a postal parcel seized in February 2018 at Malpensa airport (Italy), sent from Spain and declared as an air freshener or herbal incense, together with several other synthetic cannabinoids (Tsochatzis et al. 2021). It was notified to the EMCDDA on 9 January 2019 (Tsochatzis et al. 2021). None of this has anything to do with hemp or with cannabidiol products.
Origin
Laboratory synthesis
Entirely chemical origin: the molecule is entirely synthetic and belongs to the family of the quinolin-8-yl sulfamoyl benzoates; it differs from QMPSB, the lead compound of the series, by the difluorination of the piperidine ring (Brandt et al. 2021).
Legal framework
- European Union
It was notified to the EMCDDA on 9 January 2019 (Tsochatzis et al. 2021). It does not appear in the annex to Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which names only five synthetic cannabinoid agonists: MDMB-CHMICA, ADB-CHMINACA, CUMYL-4CN-BINACA, MDMB-4en-PINACA and 4F-MDMB-BICA, nor in annex III of the ANSM list (tables I and II of the 1971 Convention).
- France
Not cited in the consolidated ANSM list (updated 16 February 2026): no entry for « QMPSB », « 2F-QMPSB » or « SGT-13 », and its structure, an 8-quinolinol ester of a benzoic acid bearing a sulfonamide, matches none of the generic families of the synthetic cannabinoid heading of annex IV (indol-3-yl and indazol-3-yl methanones, indole and indazole 3-carboxylate and 3-carboxamide derivatives, naphthoylpyrroles, cyclohexylphenols, etc.), which cover indole, indazole or related cores.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › New psychoactive substance
- Class
sulfamoyl benzoate (quinolin-8-yl ester)
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C. Identification and Analytical Characterization of a Novel Synthetic Cannabinoid-Type Substance in Herbal Material in Europe. Molecules. 2021;26(3) (new tab)PMID 33546439
- Brandt SD, Kavanagh PV, Westphal F, Dreiseitel W, Dowling G, Bowden MJ, Williamson JPB. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233. Drug Test Anal. 2021;13(1):175-196 (new tab)PMID 32880103
- Richter MJ, Wagmann L, Brandt SD, Meyer MR. In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists 2F-QMPSB and SGT-233 Including Isozyme Mapping and Carboxylesterases Activity Testing. J Anal Toxicol. 2023;46(7):e198-e206 (new tab)PMID 36083120
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
Identifiers
Names
- Common name
- 2F-QMPSB (SGT-13)
- IUPAC name
- quinolin-8-yl 3-(4,4-difluoropiperidin-1-yl)sulfonyl-4-methylbenzoate
- Other names
- SGT-13 · QMDFPSB · 2-fluoro QMPSB
Identifiers
- Formula
- C₂₂H₂₀F₂N₂O₄S
- CAS
- 2707165-48-6
- PubChem CID
- 155884739(new tab)
- InChIKey
- JOSWCKYCXJMLNM-UHFFFAOYSA-N
- SMILES
- FC1(F)
CCN(CC1) S(= O) (= O) c2cc(ccc2C) C(= O) Oc4cccc3cccnc34
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.